In a major relief to those suffering from Hepatitis B in India, the first homegrown Hepatitis-B Vaccine called Elovac-B has been launched by the Human Biologicals Institute (HBI). With India emerging as a global medical hub—world class health care is available here at an affordable price—this launch is yet another milestone towards cementing the country’s numero uno position in the sphere. The Andhra Pradesh Finance minister, Rosaiah said on the occasion while complimenting HBI that immunity has been made affordable with the launch of Elovac-B. “There’s a need to achieve 100 per cent immunization among children and for that the Government as well NGOs should come forward to eliminate such diseases.” The vaccine, which has been prepared by HBI at a state-of-the-art plant, offers best purity and ensures best protection. The purity of Hepatitis-B surface antigen exceeds the purity specification provided by regulatory authorities.
In neighboring China, the Ministry of Health has begun a yearlong nationwide survey of the Hepatitis B situation. The survey will run till September 2007, and involves collecting blood serum samples, conducting lab tests, filing archives and making reports for future control plans. With about 100 million people suffering from Hepatitis B in China (of these approximately 20 million are chronic patients), the situation is indeed grim. Further, the government has started a two-year program aimed at preventing the spread of Hepatitis B from mother to child in four counties of Shaanxi and Gansu provinces.
The program will be first carried out in rural areas for women of childbearing age. The USD 200,000 program aims to teach nearly 340,000 women of childbearing age and nearly 600 grassroots doctors in pilot counties how to prevent Hepatitis B.
Powered by Qumana